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Thrombus is the main culprit in the pathogenesis of acute
coronary syndrome (ACS). It forms through 2 mechanisms:
ﬁrst, the adhesion, activation, secretion, and aggregation of
platelets; and the second, ampliﬁcation of the coagulation
cascade for the formation of thrombin. This requires an
activated platelet surface. Antithrombotic agents are the
mainstay of the therapy in ACS. The major goal of optimal
antithrombotic therapy for patients with ACS is to minimize
the risk of early- and long-term thrombotic adverse events, as
well as to reduce risk of bleeding complications. Antithrom-
botic therapy consists of (a) anticoagulants or antithrombin
agents and (b) antiplatelet agents. Aspirin is a cornerstone of
therapy in the treatment of patients with ACS. However, dual
antiplatelet therapy (DAPT) reduces the risk of stent thrombo-
sis and cardiovascular events compared with aspirin alone in
the treatment of patients with ACS.2 For several years,
clopidogrel plus aspirin has been the DAPT of choice for
patients with ACS undergoing percutaneous coronary inter-
vention (PCI) with stent implantation. More recently, prasugrel
and ticagrelor have demonstrated greater efﬁcacy than
clopidogrel and are getting preference over the latter.3,4
Amongst antithrombin agents, unfractionated heparin (UFH)
dominated the scene for quite some time till it faced challenge
from low-molecular weight heparins, fondaparinux, and
bivalirudin. Recently, there has been a debate as to which of
the several available anticoagulant agents should be used in
the ACS treatment regimen even though all of these have class
I recommendations in guidelines.5,6 Bivalirudin has the
advantage of lower bleeding and is often preferred over
UFH. The latest guidelines have limited the use of GPIIb/IIIa
antagonists in the management of ACS only in bailout
situations and these no longer evoke much controversy.5,6
In this issue of the Indian Heart Journal, Wayangankar and
colleagues7 have presented interesting data from USA, on the
patterns of use of antithrombotic therapy and its impact on
outcome in 64,199 patients with non-ST elevation myocardial
infarction (NSTEMI ACS) treated by PCI during 2007–2010 fromThe National Cardiovascular Data Registry's (NCDR) ACTION
Registry®-GWTGTM. The study noticed a signiﬁcant increase in
the use of UFH and bivalirudin coupled with a decrease in use
of low-molecular weight heparins and GPIIb/IIIa receptor
antagonists over a period of 4 years, which led to a signiﬁcant
decrease in major bleeding and use of blood products and a
trend toward lower mortality attributed to lower bleeding risk.
A matter of concern in this study was the underutilization of
DAPT, statins, and antirenin agents, which was not highlight-
ed. A very small number of patients were prescribed newer
antiplatelets (prasugrel mainly), as this molecule was just
getting recognition by interventional cardiologists in the
period 2007–2010.
1. Antithrombin agents and ACS
The major debate in the mind of an interventional cardiologist
is whether to use UFH (inexpensive, more familiar, subject to
monitoring and a little more bleeding) or bivalirudin (expen-
sive, less bleeding, a little more stent thrombosis). In this
context, the recently published MATRIX trial8 is of consider-
able interest. In this study of 7213 patients with ACS
undergoing PCIs, the primary and the secondary endpoints
of major cardiovascular events and net clinical beneﬁt were
similar for UFH and bivalirudin. Bivalirudin was associated
with a signiﬁcant risk of deﬁnite stent thrombosis but with
considerably less major bleeding, leading to lower mortality.
Our study also reported lower mortality in this setting.9 From
these data, it is apparent that bleeding risk algorithms should
be the prime focus when a decision has to be made about the
use of bivalirudin in the cardiac catheterization laboratory
especially in the group with high risk of bleeding. Table 1
summarizes the advantages and disadvantages of various
antithrombin agents used in management of ACS.
Each agent has strengths and weaknesses. The points of
caution with UFH are the variable response and bleeding; with
low-molecular weight heparin, it is the bleeding during
inadvertent or intended switch-over; with bivalirudin, it is
the cost and stent thrombosis, and with fondaparinux, it is the
need for additional UFH during PCI.
Table 1 – Pros and cons of various antithrombins.
PROS CONS
Unfractionated heparin Unfractionated heparin
1. Inexpensive 1. Variable efﬁcacy
2. Easily reversible 2. Needs dose monitoring
3. Proven efﬁcacy 3. Thrombocytopenia
4. Rapid action 4. More bleeding
Bivalirudin Bivalirudin
1. Linear dose–response curve 1. Expensive
2. No monitoring required 2. Often needs
postprocedure infusion
3. Less bleeding 3. More stent thrombosis
4. Rapid reversibility
5. Fixed dose
Fondaparinux Fondaparinux
1. Fixed single dose 1. Slow action
2. Less thrombocytopenia 2. Catheter thrombosis
3. Efﬁcacy regardless of
management strategy
3. Needs additional UFH
during PCI
4. Favorable safety proﬁle 4. Expensive
LMWH LMWH
1. Linear dose–response curve 1. Expensive
2. Monitoring not required 2. Switch-over is messy
3. Thrombocytopenia uncommon 3. Bleeding risk
Table 2 – Pros and cons of P2Y12 inhibitors.
PROS CONS
Clopidogrel Clopidogrel
1. Inexpensive 1. Variable efﬁcacy
2. Greater familiarity 2. Slow onset of action
3. Can be used in all cases of 3. Drug–drug interactions
4. Only agent with proven
efﬁcacy following
thrombolysis
4. Genetic response
variation
5. Once-daily dosing
Prasugrel Prasugrel
1. Rapid onset of action 1. Expensive*
2. Greater efﬁcacy in STEMI/DM 2. Major bleeding higher
3. Less drug–drug interactions 3. Use only in PCI patients
4. More effective than
clopidogrel
4. Cannot be preloaded
5. Single-daily dosing 5. Longer off-drug period
before CABG
*Generics available are cheaper
Ticagrelor Ticagrelor
1. Rapid onset and offset of
action
1. Expensive
2. Reversible platelet inhibition 2. Twice daily dosing
3. Greater efﬁcacy than
clopidogrel
3. Dyspnea and ventricular
pauses
4. Bleeding risk comparable to
clopidogrel
4. Higher non-CABG-related
bleeding
5. Mortality beneﬁt 5. Higher withdrawal rates
6. Can be used regardless of
management strategy
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DAPT in ACS for more than a decade. Supremacy of clopidogrel
has been challenged by the newer P2Y12 receptor inhibitors
like prasugrel and ticagrelor. In ACS patients with planned PCI,
in the TRITON-TIMI 38 study, prasugrel compared with
clopidogrel resulted in a better clinical outcome.10 The primary
efﬁcacy endpoint of death from cardiovascular causes,
nonfatal myocardial infarction, or nonfatal stroke occurred
in 12.1% of patients receiving clopidogrel and 9.9% of patients
receiving prasugrel (hazard ratio: 0.81; 95% CI: 0.73–0.90;
p < 0.001), at a cost of higher rates of TIMI major bleeding.
In the PLATO trial in ACS patients,11 ticagrelor compared with
clopidogrel reduced the primary endpoint of death from
vascular causes, myocardial infarction, or stroke from 11.7% to
9.8% (hazard ratio: 0.84; 95% CI: 0.77–0.92; p < 0.001). Rates of
major bleeding were similar between ticagrelor and clopido-
grel, though major bleeding not related to coronary artery
bypass grafting was more frequent in the ticagrelor-treated
patients. No studies have yet compared prasugrel and
ticagrelor in ACS patients; however, prasugrel and ticagrelor
have different side effect proﬁles, and the choice of agent
should be made either as a default choice and/or on an
individual patient basis. In the absence of head-to-head
clinical trials, network meta-analysis12 suggests potentially
relevant differences in efﬁcacy and bleeding risk among novel
antiplatelet treatments and may thereby help in understand-
ing their differential therapeutic properties. Side effects,
convenience, and cost can have a signiﬁcant inﬂuence on
drug selection. Bleeding constitutes the most common
clinically signiﬁcant safety concern of antiplatelet treatment.
The goal with any antiplatelet regimen is to balance
antithrombotic beneﬁts with the inherent risk of bleeding. A
comparison between clopidogrel, prasugrel, and ticagrelor is
shown in Table 2.In ACS patients undergoing PCI, a high on-treatment platelet
reactivity while on clopidogrel is associated with adverse
events.13 The response to clopidogrel depends on a complex
interplay of phenotypic (e.g. spontaneous platelet reactivity,
inﬂammatory status, acuity of the clinical presentation, age,
and renal function) as well as genetic variables. Genetic causes
account for insigniﬁcant response variability to clopidogrel and
hence looking for CYP2C19*2 allele to decide about using or not
using the drug is not a cost-effective strategy.
Newer P2Y12 inhibitors, such as prasugrel and ticagrelor,
are accompanied by a stronger and more consistent, anti-
platelet action14 when compared to clopidogrel resulting in
better efﬁcacy. In an adjusted indirect comparison meta-
analysis of the TRITON-TIMI 38 and PLATO trials, a head-
to-head comparison of prasugrel and ticagrelor showed no
signiﬁcant differences in overall death, myocardial infarction,
stroke, or their composite.11 Prasugrel appeared more protec-
tive from stent thrombosis, while causing more bleedings than
ticagrelor.
Clopidogrel is known to be associated with issues such as
nonresponsiveness, pharmacogenetics, drug–drug interac-
tions, and questions regarding appropriate loading dose.
Given its intrinsic limitations and inferior outcome data
compared with newer antiplatelet agents, clopidogrel may
not be an ideal drug for general use and, perhaps, should be
reserved for those with low-risk ACS or patients who
are unable to take ticagrelor or prasugrel.6 The ﬂexibility in
usage and overall ischemic beneﬁts of ticagrelor make it a very
appealing drug for managing early stages of high-risk ACS
patients. Like prasugrel, ticagrelor provides greater and more
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associated with a 22% reduction in total mortality rate
compared with clopidogrel.
It is uncommon to ﬁnd pharmacologic interventions that
result in a signiﬁcant reduction in mortality. There is no clear
explanation for the mortality beneﬁt seen with ticagrelor,
which may leave some skeptics to challenge this unexpected
ﬁnding. Indirect comparison between prasugrel and ticagrelor
showed that ticagrelor was superior in efﬁcacy to prasugrel for
chronic preventive use because of absolute mortality rate
reduction, recurrent MI prevention, outcome beneﬁt that
continues to grow over time, fewer hemorrhagic fatalities,
and potentially fewer CABG surgery-related bleeding event.11
2. Switch strategy
As ACS-related PCI increase in number and complexity, more
patients must be treated with prolonged and intensiﬁed
antiplatelet therapy. Objective view must be taken of each
DAPT strategy. With clopidogrel, it is a variable response; with
prasugrel, it is bleeding; and with ticagrelor, it is the cost. How
do we determine which agent is best for a particular patient?
There is no simple answer. Ticagrelor is a good compromise
when balancing ischemic and bleeding risk with additional
trump card of reduced mortality. Patients loaded initially with
clopidogrel can be switched to ticagrelor with a loading dose.
Similarly, patients can be switched over to prasugrel from
clopidogrel before PCI with a maintenance dose if clopidogrel
loading dose had already been administered in the previous
few days.
The agent ticagrelor or prasugrel needs to be continued
uninterrupted for 1 year as per the most accepted protocols.
Continuation of DAPT beyond one year is a matter of current
interest as the beneﬁts in ischemic events have been shown at
the cost of increasing bleeding. Last word on this subject is still
to come.
There also is a thought of switching back to clopidogrel
after a period when ischemic risk has come down with
reduction in costs and bleeding events. The concept can
increase events in those patients who are clopidogrel resistant
and hence platelet reactivity tests should be considered. We
need more data in the form of randomized studies before
recommending this strategy.
Ticagrelor binds reversibly to P2Y12 receptor. The reversible
action makes it attractive for situations when DAPT needs to
be interrupted. Prasugrel is a good alternative in those patients
of ACS who undergo PCI with high ischemic risk and low
bleeding risk. It is best suited for relatively young patients with
ACS and diabetes and especially in those who have once
experienced stent thrombosis or recurrence of ACS on
clopidogrel therapy. Ticagrelor has the additional advantage
of providing better efﬁcacy even in those patients not going for
PCI and continuing medical therapy unlike prasugrel, which is
to be used only in patients undergoing PCI.
Clopidogrel is still the preferred drug in those with low
ischemic burden and high bleeding risk. The special situations
are in those patients who have received thrombolysis or those
with deranged renal function or very elderly people. Prasugrel
should not be used in patients with low body weight, veryelderly, and with a history of stroke or transient ischemic
attack. If ticagrelor is used, the dose of aspirin must be
<100 mg daily. The use of GPIIb/IIIa blockers should be kept
only for patients undergoing PCI for a bailout situation and
their routine use should be discouraged. Intravenous Can-
grelor if available is meant for patients who are antiplatelet
drug naive and are being taken up for acute STEMI.
3. Conclusion
The use of newer agents like ticagralor and prasugrel in
patients with intermediate- and high-risk ACS should be
preferred given their proven superiority in robustly designed
trials against clopidogrel. The indications for ticagrelor are
wider in that it can be given before knowing coronary anatomy
and also have a place in patients going on medical treatment
alone unlike prasugrel, which has very speciﬁc indications
during and after PCI for ACS. Cangrelor is the drug to bridge the
gap between the onset of action of newer drugs, which can
take up to a few hours after administration in sick patients
with STEMI. In all situations, the clinical efﬁcacy has to be
balanced against bleeding.
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